Louisiana State Employees Retirement System Sells 1,100 Shares of Xencor, Inc. (NASDAQ:XNCR)

Louisiana State Employees Retirement System lowered its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 3.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,900 shares of the biopharmaceutical company’s stock after selling 1,100 shares during the period. Louisiana State Employees Retirement System’s holdings in Xencor were worth $601,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Quarry LP bought a new position in shares of Xencor during the second quarter worth approximately $36,000. SG Americas Securities LLC bought a new position in shares of Xencor during the second quarter worth approximately $154,000. XTX Topco Ltd bought a new position in shares of Xencor during the second quarter worth approximately $196,000. Acadian Asset Management LLC bought a new position in Xencor during the 1st quarter worth $206,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Xencor during the 2nd quarter worth $212,000.

Xencor Stock Performance

Shares of XNCR opened at $21.52 on Wednesday. Xencor, Inc. has a 52-week low of $15.31 and a 52-week high of $26.84. The business’s fifty day moving average is $20.10 and its 200-day moving average is $20.19. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.92 and a current ratio of 6.92. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -7.45 and a beta of 0.66.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.25). Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The firm had revenue of $16.96 million for the quarter, compared to analyst estimates of $21.13 million. During the same period last year, the business earned ($0.37) EPS. The company’s revenue was down 62.7% compared to the same quarter last year. Equities analysts anticipate that Xencor, Inc. will post -4.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

XNCR has been the topic of a number of recent research reports. BMO Capital Markets restated an “outperform” rating and set a $32.00 price objective on shares of Xencor in a research note on Tuesday, August 6th. Wedbush restated an “outperform” rating and set a $34.00 price objective on shares of Xencor in a research note on Monday, September 9th. Royal Bank of Canada raised their price objective on Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Thursday, September 26th. Finally, JPMorgan Chase & Co. lowered their price objective on Xencor from $30.00 to $27.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.78.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.